Business
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
EQUALISE Phase 1b Study in lupus nephritis fully enrolled – topline data in early 2024 LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a
About this update from Equillium, Inc.
[{"type":"text","content":"\nEQUALISE Phase 1b Study in lupus nephritis fully enrolled – topline data in early 2024\n\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR). ASN is taking place at the Pennsylvania Convention Center in Philadelphia, PA, November 1 – 5, and ACR is taking place at the San Diego Convention Center in San Diego, CA, November 10 - 15.\n\n\nThe abstracts highlight data from 17 Type B subjects in the Phase 1B EQUALISE study in highly proteinuric lupus nephritis patients (mean 24-hour urine protein creatinine ratio (UPCR) > 4 g/day). The data demonstrate that subjects had high complete and partial response rates with rapid and deep reduction in UPCR when itolizumab was added to mycophenolate mofetil and corticosteroids. This is in the setting of tapering the corticosteroids, stable kidney function (eGFR) and increasing serum albumin while on study. Itolizumab was well tolerated when treated every 2 weeks for 24 weeks; with only 2 subjects reporting serious adverse events.\n\n\nAmerican Society of Nephrology American College of Rheumatology\nTitle: EQUALISE Type B: Clinical results of itolizumab, a novel anti-CD6 therapy, in subjects with lupus nephritis\nAuthor: Dr. Kenneth Kalunian, Professor, Medicine, UCSD School of Medicine\nPoster Number: SA-PO875\nAssigned Session: Glomerular Diseases: Therapeutics\nDate and Time: November 4, 10:00 am ET – 12:00 pm ET\n\n\nAmerican College of Rheumatology\nTitle: Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis\nAuthor: Dr. Kenneth Kalunian, Professor, Medicine, UCSD School of Medicine\nAbstract Number: 1496\nAssigned Session: SLE – Treatment Poster II\nDate and Time: November 13, 9:00 am ET – 11:00 am PT\n\n\nThe abstracts are available on the ASN website and ACR website. Poster presentations will be available on the Presentations page of Equillium’s website under the Lupus tab.\n\n\nAbout Systemic Lupus Erythematosus (SLE)...